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a b s t r a c t
Background: Breast cancer is the most common cancer and second cause of death in women worldwide.
Patients with breast cancer are classified into subgroups based on the presence or absence of hormone
receptors and the human epidermal growth factor 2-neu (HER-2) marker, the different molecular profiles
come with an associated prognosis and variety of possible treatment options. Patients with triple nega-
tive cancer have a worse prognosis, a more aggressive behavior, higher likelihood of spreading, a higher
risk of recurrence and a poorer outcome overall. Intramedullary rod fixation has proven to provide a good
outcome and function in patients with metastatic breast cancer, but no study has addressed the receptor-
status potential outcome differences that may affect disease progression at an orthopaedic surgery site.
Questions/Purposes: (1) Do patients with triple negative breast cancer have a higher revision rate of intra-
medullary rod fixation of bone metastases? (2) Do patients with metastatic triple negative breast cancer
have a higher revision rate of intramedullary rod fixation due to local disease progression?
Methods: This was a single-center, observational, retrospective cohort study. Fifty-seven patients with a
diagnosis of breast cancer metastatic to long bones who underwent surgical fixation with an intramedul-
lary rod for a pathological fracture or an impending fracture due to a bone metastasis with a Mirels’ score
equal or above 8 between January 2004 and December 2016 at our institution were included. All implants
used were from the same manufacturer (Stryker Corp., Mahwah, NJ, USA). Patients were divided into two
groups based on the receptor status of the tumor and were classified either as triple negative, when the
tumor lacked progesterone, estrogen and HER-2 receptors, or as receptor-positive when the presence of
one or a combination of either three was proven. In the triple-negative tumor group the mean follow up
time was 26 months (SD 29) and median follow up time was 16 months. In the receptor-positive tumor
group mean follow up was 27 months (SD 24) with a median follow up of 19 months. To assess possible
associations between different factors and the outcomes of interest, we used either the chi-square test or
Fisher’s exact test for categorical variables and the ANOVA test for continuous variables. For the survival
assessment, a Kaplan-Meier analysis was performed and for the cumulative incidence a competing risk
analysis was utilized.
Results: The intramedullary rod revision rate for patients in the triple-negative tumor group was 17%,
while for the receptor-positive group it was 12%, this was not statistically different for our sample size.
The mean time for revision of the intramedullary rod in the whole sample was 19 months (SD 11, range
6–40). The causes of revision were disease progression (43%), nonunion (29%) and surgeon error (29%).
The cumulative incidence of revision surgery was 6% (CI 95%, 2–14%) at 12 months and 20% (CI 95%,
8–36%) at 60 months.
Conclusions: Intramedullary rodding can be considered for the treatment of long bones metastases in
breast cancer patients for an impending or actual pathological fracture. There is no difference in the intra-
medullary rod revision rate among patients with different receptor-status when comparing triple-
negative tumor patients and receptor-positive ones.
Level of Evidence: Level III, therapeutic study.
 2021 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Breast cancer is the most common cancer and second cause of
death in women worldwide [1,2]. It is estimated that in 2019 there
will be more than 260,000 new cases in the United States [3]. The
incidence has remained stable for Caucasian women but has
slightly increased for African American women [3]. Bone is the
most common site of disease spread, and the factors associated
with it are well known [4]. Breast cancer is very heterogenous with
different molecular profiles; patients are divided into subgroups
based on the presence or absence of hormone receptors and the
human epidermal growth factor 2-neu (HER-2) marker [5,6].
Depending on the receptor-status, patients have different thera-
peutic options and prognosis. The most common breast cancer
subtypes are estrogen or progesterone receptor positive [7].
Tumors with absence of these three receptors, progesterone, estro-
gen and HER-2, are known as triple-negative cancers. This status is
more frequent among young women and African Americans [8,9].
Patients with triple negative tumors have fewer therapeutic
options, besides cytotoxic chemotherapy [10]. Additionally, those
patients with a triple negative cancer have a worse prognosis as
these tumors appear to have a more aggressive behavior, with
higher likelihood of spreading, a higher risk of recurrence and a
poorer outcome overall [11–14].
Disease spread limited to the skeletal system is associated to
better prognosis when compared to the presence of visceral metas-
tases [15,16]. Patients with bone metastases despite the better
prognosis, are prone to skeletal related events (SRE) that require
medical and/or surgical interventions. SRE are associated with
pain, pathologic fractures, spinal cord and/or nerve compression
and hypercalcemia and are a significant source of morbidity for
these patients [17]. Bisphosphonates have been shown to reduce
the risk of developing SRE, delay the median time to an SRE, and
appear to reduce bone pain when compared to placebo or no bis-
phosphonate [18].
Previous studies have demonstrated a good outcome and func-
tion with intramedullary rod fixation for long bone impending or
pathologic fractures in metastatic cancer patients [19–21]. To the
best of our knowledge no previous studies have specifically
focused on breast cancer receptor-status, with its different behav-
iors, disease progression risks, prognosis and treatment options,
and its potential effect on implant survival.
We therefore asked: (1) Do patients with triple negative breast
cancer have a higher revision rate of intramedullary rod fixation of
bone metastases? (2) Do patients with metastatic triple negative
breast cancer have a higher revision rate of intramedullary rod fix-
ation due to local disease progression?
2. Patients and methods
2.1. Description of experiment, treatment, or surgery
This was a single-center, observational, retrospective cohort
study. In our surgical database we identified patients with a diag-
nosis of breast cancer metastatic to long bones who underwent
surgical fixation with an intramedullary rod between January
2004 and December 2016 at our institution. Patients with a breast
tumor other than an adenocarcinoma, such as phyllodes, sarcoma
or lymphoma among others, were not included. Additionally,
patients with other types of implant, such as endoprosthesis or
plates and screw osteosynthesis, either as a single fixation method
or in addition to an intramedullary rod in the index procedure,
were excluded from the analysis as well. All operations were per-
formed by fellowship-trained surgeons at a tertiary center in
patients with a pathology proven diagnosis. Patients were recom-
mended for the surgical procedure either due a pathological frac-
ture of a long bone, defined as a cortex breach with or without
displacement, where a metastatic lesion was observed, or an
impending fracture due to a bone metastasis in a long bone, but
no actual cortex fissure, in patients with a Mirels’ score equal or
above 8 [22]. Lesions in the proximal or distal third with severe
bone destruction that precluded nail end-fixation were indicated
for an endoprosthetic replacement, and not included in this analy-
sis. Cement augmentation was added at the surgeon’s preference.
All implants used were from the same manufacturer (Stryker Corp.,
Mahwah, NJ, USA). Immediately after the surgical procedure all
patients were allowed to bear weight in the operated extremity
as tolerated. For the upper extremity procedures, a sling was occa-
sionally prescribed for comfort and for the lower extremity nails,
crutches or walkers were recommended at the physical therapist’s
discretion.
Operative reports, clinic notes, and radiographs were analyzed.
Patients were followed for a minimum of 24 months or until death
or revision surgery was performed.
More than 300 records of patients treated by the oncology
orthopedic service during the study period were reviewed. Of
these, 57 met the inclusion criteria and were submitted to analysis
(Fig. 1). The patients were divided into two groups based on the
receptor status of the tumor and were classified either as triple
negative, when the tumor lacked progesterone, estrogen and
HER-2 receptors, or as receptor-positive when the presence of
one or a combination of either three was proven. Six patients were
included in the triple-negative tumor group and the remaining 51,
who had at least one receptor present, were added to the receptor-
positive group.
In the triple-negative tumor group the mean follow up time was
26 months (SD 29) and median follow up time was 16 months. In
the receptor-positive tumor group mean follow up was 27 months
(SD 24) with a median follow up of 19 months. The mean follow up
times among groups were not found to be different for this sample
size. Three patients died in the triple-negative tumor group and
fourteen died in the receptor-positive one.
2.2. Variables, outcome measures, data sources, and bias
Demographic information as well as receptor status, treatments
received, surgery indication and type of implant utilized were
recorded. In addition, plain radiographs were reviewed by two
fellowship-trained oncology orthopedists. There were no conflict-
ing opinions regarding the failure diagnoses. The rod was consid-
ered to have failed when a surgical revision procedure was
required either due to hardware mechanical failure, disease pro-
gression, surgeon error (i.e., inappropriate implant choice or surgi-
cal technique error), or non-union of a fracture.
Patient demographics at presentation were compared among
the two groups (Table 1). All patients in our cohort were female.
The mean age in our full cohort was 59 years old (range 31–
89 years). All patients had pathology proven metastatic breast
adenocarcinoma.
In the triple-negative tumor group, the mean age was 62 (SD 12,
range 47–77), for our second group, with the receptor-positive
tumors, the mean age was 59 (SD 12, range 31–89). The age distri-
bution among groups was found not different for our sample size.
Regarding the surgically treated lesion location, in the triple-
negative tumor group 67% (4 of 6) had a humeral lesion that
required rodding, for the remaining of the group, it was a femoral
lesion (2 of 6). In the receptor-positive group 65% had a femoral
metastatic lesion (33 of 51) and 35% had a humerus located lesion
(18 of 51). The location distribution was not different for the sam-
ple size. In the triple-negative tumor group, 33% of the patients (2
of 6) had an actual fracture, while the remaining 67% had an
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impending fracture (4 of 6). In the other group, also 33% had an
actual fracture (17 of 51), and 67% had an impending fracture
(34 of 51). Likewise, distribution was not different for the sample
size. In both groups, all patients with humeral lesions, had an intra-
medullary type of nail, while for the patients with femoral lesions,
those with a proximal third location but no extension to the
femoral neck or head, had a cephalomedullary type of nail inserted.
Patients with a mid-diaphysis metastatic lesion, received an intra-
medullary type of nail. In our sample, no patient had a lesion distal
enough to require a retrograde nail, all nails inserted in both
groups were in anterograde fashion. In the triple-negative tumor
group, 33% had a cephalomedullary rod inserted (2 of 6), the
remaining patients in this group had all humeral lesions, with an
intramedullary humeral device utilized for fixation. In the
receptor-positive tumor group, 55% (28 of 51) had a cephalomedul-
lary type of rod, 45% (23 of 51) had an intramedullary nail, this
included all the humerus lesion patients (18 patients) and 5 intra-
medullary femoral nails. The type of fixation device distribution
was not different for our sample size. In the triple-negative group
33% (2 of 6) had cement augmentation added to the rod fixation,
both patients had surgery for fixation of a humeral lesion. In the
other group, 18% (9 of 51) had cement augmentation added during
the nail fixation procedure for either humeral or femoral lesions.
This distribution was not different among the two groups for our
sample size.
From the breast cancer standpoint, 83% (5 of 6) in the triple-
negative group had multiorgan disease spread, including lung, liver
and/or brain, besides the bone lesions. In the receptor-positive
group, 78% (40 of 51) had disease spread to multiples sites other
than bone. The remaining of patients in both groups, had only bone
metastatic disease without any evidence of visceral secondary
lesions. No difference was found for this distribution for our sam-
ple size. For the patients’ performance status the Karnofsky scale
was used [23]. In the triple-negative tumor group, 50% (3 of 6)
had a scale of 80 (able to carry normal activity with effort) and
the remaining 50% (3 of 6) had a scale of 70 (cares for self, unable
to carry normal activity). In the receptor-positive group, 37% (19 of
51) had a scale of 70 and 29% (15 of 51) had a scale of 80, the range
for this group was 50–90 and values other than 70 or 80 were pre-
sent in smaller percentages (Table 2). The distribution for the
Karnofsky scale among the two groups was not found to be differ-
ent for our sample size. In terms of antiresorptive therapy, in the
triple-negative tumor group, 33% (2 of 6) were receiving bisphos-
Fig. 1. Chart depicting the STROBE patient selection flow chart used in our sample, showing a total recruited n = 62 and total available for analysis n = 57.
Table 1
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phonate treatment at the time of the surgical procedure, the
remaining 67% (4 of 6) were not taking any antiresorptive drugs.
In the receptor-positive group, 43% (22 of 51) were taking bispho-
sphonates and 8% (4 of 51) were receiving denosumab as antire-
sorptive treatment, the remaining 49% (25 of 51) were not
receiving any antiresorptive drugs at the time of the surgical pro-
cedure or previously. Two patients in the receptor-positive group
who were receiving bisphosphonates had jaw osteonecrosis as a
treatment related complication. This distribution was not different
for our sample size. Three patients (50%) had radiation to the lesion
after the surgical procedure in the triple-negative tumor group and
the remaining three (50%) of that same group did not receive any
radiation at all. In the receptor-positive group 16% (8 of 51) had
radiation therapy prior to the surgical procedure, 43% (22 of 51)
received it postoperatively and the remaining 41% (21 of 51) did
not receive radiotherapy at all. The radiotherapy distribution
among the two groups was not found to be different for our sample
size. In the triple-negative tumor group 33% (2 of 6) were receiving
systemic chemotherapy, 33% (2 of 6) were receiving hormonal
therapy; these patients initially had a hormone-positive tumors
but were discovered to have changed to a triple-negative cancer
when a biopsy during the rodding surgical procedure was
obtained; and the remaining 33% (2 of 6) was not receiving any
treatment since the breast cancer was diagnosed with the biopsy
from the rodding surgery. In the receptor-positive group 63% (32
of 51) were receiving hormonal therapy, 12% (6 of 51) were on
chemotherapy, 10% (5 of 51) were under targeted therapy, 6% (3
of 51) were receiving a combination of either chemotherapy and
targeted therapy (one patient), or chemotherapy and hormone
therapy (one patient) or targeted and hormone therapy (one
patient). Five patients in this group were not receiving any sys-
temic oncologic treatment, in four of them the breast cancer was
diagnosed with the biopsy obtained during the intramedullary
rod surgery and the other fifth patient refused any form of sys-
temic treatment. No patient of any group was receiving
immunotherapy.
Our primary study endpoint was surgical revision of the intra-
medullary rod, and we assessed the different rates in the group
with triple-negative tumors and the one with receptor-positive
tumors. We tested this by comparing the cumulative incidence of
our endpoint in the two different groups. Among the groups the
surgical indications were identical; patients with a pathology pro-
ven diagnosis of breast adenocarcinoma metastatic to long bone
withe either a pathological fracture of a long bone where a meta-
static lesion was observed or an impending fracture due to a bone
metastasis in a long bone with a Mirels’ score equal or above 8.
Additionally, implants from the exact manufacturer (Stryker Corp.,
Mahwah, NJ, USA) were used in both groups as well.
Our second study question was the incidence of intramedullary
rod revision specifically due to disease progression, compared
among our two groups, one only with triple-negative tumors and
thus less systemic treatment options and worse prognosis associ-
ated, and the other groupwith receptor-positive tumors and awider
array of systemic treatment options available as well as a more
benign prognosis. Failure of the implant leading to revision due to
disease progression was defined as an increase in the metastatic
lesion area observed on radiographic images of the bone in question
and compared to the same radiographic images at the timeof the ini-
tial surgery causing the implant tomechanically fail (break) or caus-
ing enough symptoms, such as increasing pain or inability to bear
weight, to warrant the surgeon to proceed with a revision prior to
the actual mechanical failure of the rod. This was tested by compar-
ing the different incidence of intramedullary rod revision due to dis-
ease progression among the different groups.
Additionally, the intramedullary rod revision cumulative inci-
dence in metastatic breast cancer patients was assessed through
a competing risk analysis with death as a competing event. More-
over, the patients’ overall survival was determined by a Kaplan-
Meier analysis and the difference in survival among the two groups
was assessed by a log-rank test.
2.3. Statistical analysis, study size
We performed statistical analyses with SPSS Statistical Soft-
ware, version 25.0 (IBM Inc., Armonk, NY, USA) and for the compet-
ing risk analysis we utilized R version 3.5.3 (R Foundation for
Statistical Computing, Vienna, Austria). To assess possible associa-
tions between different factors and the outcomes of interest, we
used either the chi-square test or Fisher’s exact test for categorical
variables and the ANOVA test for continuous variables. For the sur-
vival assessment, a Kaplan-Meier analysis was performed and for
the cumulative incidence a competing risk analysis was utilized.
All tests were deemed significant if p was < 0.05.
3. Results
The intramedullary rod revision rate for patients in the triple-
negative tumor group was 17% (1 of 6). In the receptor-positive
group the revision rate of intramedullary devices was 12% (6 of
51). Despite the rate being smaller in the receptor-positive group
this was not significantly different for the sample size. The mean
time for revision of the intramedullary rod in the whole sample
was 19 months (SD 11, range 6–40).
Among the patientswhounderwent a revisionof the intramedul-
lary nail (n = 7), three had the initial surgery indicated for an actual
pathological fracture, while the remaining four had the initial rod
fixation for an impending fracture in a symptomatic patient with a
Mirels’ score equal or above8 (Table 2). This distributionwasnot dif-
ferent for the sample size. Additionally, among these same patients
who needed a revision surgery, only one had cement augmentation,
while the other six did not and this was not statistically different.
Five patients had surgery for a metastatic lesion in the femur, while
the remaining two had a humerus lesion. The anatomical location
distribution was not different for our sample size.
Table 2
Table depicting the revision patients’ demographic characteristics.
Patient Receptor-status Location Fracture Failure Type Time to Revision Treatment
47, F Receptor + Femur No Disease Progression 26 Curettage + Cement
51, F Receptor + Femur No Disease Progression 22 Amputation
52, F Receptor + Femur No Surgical error 40 Rod Exchange
77, F Triple Negative Humerus No Disease Progression 12 Distal Humerus Replacement
59, F Receptor + Humerus Yes Nonunion 8 Rod Exchange
62, F Receptor + Femur Yes Surgical error 6 Rod Exchange
59, F Receptor + Femur Yes Nonunion 22 Rod Exchange
Time to Revision in months, F = Female.
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The odds ratio of a patient with a triple-negative tumor with an
intramedullary rod fixation of a metastatic lesion to necessitate a
revision of the implant compared to those patients in the
receptor-positive group in the same situation is OR = 1.5, CI 95%
0.15–15.11; this was not statistically different.
Two patients in the receptor-positive group (2 of 51) needed a
revision of the intramedullary rod due to progression of the dis-
ease, while that was the cause for revision in only one patient in
the triple-negative tumor group (1 of 6). This distribution was
not different for our sample size.
Among all the patients that required a revision procedure, the
most frequent cause was disease progression with 43% (3 of 7), fol-
lowed by nonunion in 29% (2 of 7) and surgeon error in the same
frequency, 29% (2 of 7) (Table 2). Of the patients with a nonunion,
one had radiotherapy prior to the procedure and the second
patient refused radiation treatment. Regarding the failures catego-
rized as surgical error, those included the absence of distal rod fix-
ation and suboptimal positioning; the later initially performed at
an outside institution.
In the group of patients who required a revision of the intra-
medullary rod (n = 7), six where receiving hormonal therapy at
the time of the revision and the seventh one refused any sys-
temic treatment and died soon after. Two of the patients
received radiation to the lesion surgically fixated prior to the ini-
tial surgery, three did it after the intramedullary rod was in
place and two refused radiotherapy. Four of the seven patients
were receiving bisphosphonates, none was receiving denosumab
and three were not taking any antiresorptive drugs. None of
these factors showed a difference in affecting the revision out-
come for our sample size.
In a competing risk analysis with death of the patient as the
competing event, the cumulative incidence of revision surgery
Fig. 2. The cumulative incidence of revision surgery with death of the patient as a competing risk.
Fig. 3. Kaplan-Meier analysis of the overall patient survival with CI95%.
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was 6% (CI 95%, 2–14%) at 12 months and 20% (CI 95%, 8–36%) at
60 months (Fig. 2).
With the Kaplan-Meier analysis, the overall patient survival was
81% (CI 95%, 70–92%) at 12 months and 53% (CI 95%, 35–81%) at
60 months (Fig. 3). The survival was not different when comparing
among groups for our sample size.
4. Discussion
Breast Cancer is the most common cancer affecting women,
about eighty percent of these patients will develop bone metas-
tases at some point in their disease course and this is the most
common site for secondary disease spread [4,1]. Advances in treat-
ment options, which now include hormonal therapy, chemother-
apy, targeted therapy and immunotherapy, have taken the 5-year
survival rate to 89% currently in the United States, with the main
cause of death remaining the distant lesions [24]. Unfortunately,
despite all these improvements, triple-negative tumors continue
to be considered the most aggressive subgroup with fewer treat-
ment possibilities [25,26]. This subgroup accounts for 15% of the
breast cancer diagnoses and is known for its heterogeneity, aggres-
sive evolution and higher risk of recurrences [10]. No prior study
has addressed if this behavior difference would also affect the sur-
vival of intramedullary rodding; a common treatment option for
bone metastases that do not require resection; in these patients.
Osseous spreading puts in action a vicious cycle involving osteo-
clast interaction with cancer cells and its concurrent activation,
leading to pathological bone destruction and fractures [27]. Long-
lasting bone fixation is paramount in these patients who now are
living longer to maintain mobility and a good quality of life [4].
Additionally, it is of high importance for the treating oncology
orthopedist to understand the differences in behavior, prognosis
and adjuvant treatment response in the different breast cancer
subgroups. In our study we found an overall revision rate of the
intramedullary rods of 12%, with a higher rate (17%) in the
triple-negative tumor subgroup compared to the receptor-
positive section of the sample (12%). Moreover, our data suggests
that the overall cumulative incidence of revision surgery was 6%
at the first year from the index surgery and 20% at 5 years from
the initial procedure, which may be higher in the future as patients
survive longer with better systemic treatment. Previous literature
demonstrated that hormone-receptor positive patients have a higher
risk of having bone metastatic disease, but concomitantly these same
patients also tend to have a better prognosis, with better treatment
response and longer overal survival [9,28,29,13,14]. Earlier studies
have shown that the most important factor for bone fixation failure
was the length of the patient’s survival [30,31]. In accordance with
this, our data showed that patients with metastic breast cancer trea-
ted with intramedullary rods required a late revision with a mean
time for the revision procedure of 19.4 months. This suggests sur-
geons should be congnizant of the fact that their fixation may need
to outlive the initial 6-month interval. Additionally, our study
showed a higher rate of femur nail failure (14%, 5 of 35) compared
to humerus nail failure (9%, 2 of 22), that difference was not signifi-
cant for our sample size, but may be a refelection of different fre-
quency of failure modes for upper extremety (non-weightbearing)
devices compared to lower extremity ones. Prior studies have shown
that humerus nail failure rates can be up to 10% due to non-union,
whereas femur nails can undergo mechanical failure with implant
breakage in up to 16% with an important percentage of those (41%)
occurring in patients treated for a pathological fracture [32,33].
One might expect that fixation in triple negative disease
patients would require more revisions due to progression of triple
negative disease locally at the site of fixation. However this was
not seen likely due to the fact that with local progression also
comes significant systemic progression of triple negative disease
that leads to the passing of the patient. Aggressive systemic pro-
gression allows for the local fixation to outlast the patient’s life
expectancy. In the future as treatments become better and lead
to longer life expectancy one will likely see a higher revision rate
that might suggest a different index surgical procedure should be
performed, i.e., either segmental replacement or arthroplasty.
Surprisingly, this study also showed that although radiation
oncologists routinely recommend postoperative radiation to the
surgical site post-fixation this is not always accomplished. Typi-
cally, radiation is delivered locally to minimize disease progression
at the operative fixation site and thus to prevent future hard-
ware failure. Our study indicated that not all the patients received
radiation at the fixation site. Those who were not irradiated pre-
sented no more risk for fixation failure than the patients who did
receive radiotherapy to the affected bone. This is may be due to
the novel superior treatment options involving targeted therapy
and newer chemotherapy alternatives. Further studies will be
needed to better elucidate this phenomenon. These patients may
benefit from a multidisciplinary breast cancer team that should
include discussions with the orthopaedic surgeon or orthopaedic
oncologist. An additional unexpected finding was that only 51%
of the patients (29 of 57) included in the study were receiving
antiresorptive bone therapy at the time of the fracture or previ-
ously. Bone metastases present with an imbalance between bone
resorption and bone remodeling, favoring the former. Bisphospho-
nates have a proven role in altering this phenomenon and prevent-
ing fractures and other SREs; members of the multidisciplinary
treating team must be mindful of this [18].
5. Limitations
This study had a number of limitations. First, our sample was of a
relatively reduced size, with a total of 57 patients, and even though
this was the biggest sample we found in the literature regarding
specifically metastatic breast cancer and its treatment exclusively
with intramedullary rodding, we acknowledge we did not have
enough power to achieve significance in our results [30,20]. For the
difference in revision rate among the different groups, 12% vs. 17%,
our study attained to show a trend in the association between hor-
mone receptors and rod survival, unfortunately those numbers did
not reach statistical significance and our sample size likely played a
role in that. For such rate difference, our study would have needed
a sample of over 1500 patients and for such specific scenario that
would entail a multicentric study. Secondly, we may have incurred
in a selection bias, including patients who in addition of the intrame-
dullary rodding underwent excision of the metastatic lesion by
means of curettage and cementing. By excising the secondary focus
of disease, those patients would have had a lower risk of revision
due to disease progression, but our results showed that the distribu-
tion of these patients was not different among the two groups nor did
it affect the revision outcome. Additionally, among the patients who
did not need a revision or died, the triple -negative tumor group had
a higher percentage of patients not seen in the past 5 years (17%, 1 of
6), compared to the receptor-positive group (8%, 4 in 51). While this
may be considered as a retention bias our analysis showed that this
distribution was not different for our sample size. Furthermore,
regarding the number of deaths in each group, those were also not
different for the number available. Our institution is the only National
Cancer Institute (NCI)-designated Comprehensive Cancer Centers in
the state, as such we have patients coming from long distances
who eventually continue their follow up locally, in such circum-
stances we acknowledge that we could have underestimated the
overall rod revision rate. Fourthly, cancer patients may present with
a compromised performance status, and those bedridden or with lim-
ited activity may have a lower risk of experiencing rod failure symp-
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toms. Nevertheless, any potential performance bias, was reduced by
taking the Karnofsky score of our patients into our analysis. The
Karnofsky score is a performance scale which assesses patients
according to their functionality with a prognostic implication. The
median Karnofsky score was not different among the two groups,
75 for the triple-negative tumor group and 70 for the receptor-
positive group. Additionally, the systemic treatment and radiother-
apy exposure was also not different among the groups; thus, the
average effect of activity level on the rod survival was probably not
different as well. Our study showed that most of these patients had
multiorgan metastatic disease (79%) nonetheless presented with a
good performance status, with 49% of the patients having a Karnofsky
score equal or above 80 (able to carry on normal activity and to work)
and 88% with a score equal or above 70 (able to live at home and care
for most personal needs), emphasizing again the importance of pro-
viding good long-lasting bone fixation. An additional limitation of
our study is the lack of information regarding the bone density status
of the patients. Previous studies have demonstrated that breast cancer
patients due to treatment induced ovarian failure are at risk for
decreased bone density and this may have potentially played a role
in implant failure [34]. Lastly, we only utilized implants from the same
manufacturer, which could also be considered a strength of our study
since by doing so we reduced other confounding variables, but corre-
spondingly by doing so our results may not extrapolate to implants
produced by other manufacturers which may have different results
in this same scenario. We also acknowledge that not all the patients
received postoperative radiation as would be recommended in this
scenario; nonetheless our data suggests that there was no increased
risk to nail failure in the absence of postoperative radiotherapy.
6. Conclusions
Intramedullary rodding can be considered for the treatment of
long bones metastases in breast cancer patients in the setting of
an impending or actual pathological fracture. There is no difference
in the intramedullary rod revision rate among patients with differ-
ent receptor-status when comparing triple-negative tumor
patients and receptor-positive ones. Diligent attention to the
longer expected survival of these patients, especially those with
bone as the sole site of spread, and the late failure time is recom-
mended and should be taken into account when making treatment
decisions.
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